{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T10:30:54Z","timestamp":1772101854577,"version":"3.50.1"},"reference-count":31,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"2","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JOP"],"published-print":{"date-parts":[[2017,2]]},"abstract":"<jats:sec><jats:title>Purpose:<\/jats:title><jats:p> The number of targeted oral anticancer medications (TOAMs) has grown rapidly in the past decade. The high cost of TOAMs raises concerns about the financial aspect of treatment, especially for patients enrolled in Medicare Part D plans because of the coverage gap. <\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p> We identified patients with chronic myeloid leukemia (CML) who were new TOAM users from the SEER registry data linked with Medicare Part D data, from years 2007 to 2012. We followed these patients throughout the calendar year when they started taking the TOAMs and examined their out-of-pocket (OOP) payments and gross drug costs, taking into account their benefit phase, plan type, and cost share group. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p> We found that 726 (81%) of the 898 patients with CML who received TOAMs had reached the catastrophic phase of their Medicare Part D benefit within the year of medication initiation, with a large majority of patients reaching this phase in less than a month. Patients without subsidies showed a clear pattern of a spike in OOP payments when they began treatment with TOAMs. The OOP payment for patients with subsidies was substantially lower. The monthly gross drug costs were similar between patients with and without subsidies. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p> Patients experience quick entry and exit from the coverage gap (also called the donut hole) as a result of the high price of TOAMs. Closing the donut hole will provide financial relief during the initial month(s) of treatment but will not completely eliminate the financial burden. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jop.2016.014639","type":"journal-article","created":{"date-parts":[[2017,2,23]],"date-time":"2017-02-23T14:50:48Z","timestamp":1487861448000},"page":"e152-e162","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":21,"title":["Financial Burden for Patients With Chronic Myeloid Leukemia Enrolled in Medicare Part D Taking Targeted Oral Anticancer Medications"],"prefix":"10.1200","volume":"13","author":[{"given":"Chan","family":"Shen","sequence":"first","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, TX; and Northwestern University, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Zhao","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, TX; and Northwestern University, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Liu","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, TX; and Northwestern University, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Chen Tina","family":"Shih","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, TX; and Northwestern University, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"B4","doi-asserted-by":"crossref","unstructured":"Einav L, Finkelstein A, Schrimpf P: The response of drug expenditure to non-linear contract design: Evidence from Medicare Part D. Q J Econ 130:841-899, 2015","DOI":"10.1093\/qje\/qjv005"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/hec.2981"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000135"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.2320"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2013.001167"},{"key":"B9","first-page":"118","volume":"8","author":"Kleinke JD","year":"2015","journal-title":"Am Health Drug Benefits"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2014.0001"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2014.0558"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2015.003772"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1586\/14737167.2014.868310"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.9123"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.19.2344"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa030954"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.62.4.435"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.3179"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2012.0174"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1001\/jama.298.1.61"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1475-6773.2009.01059.x"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0168"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2012-0279"},{"key":"B24","first-page":"s78","volume":"22","author":"Doshi JA","year":"2016","journal-title":"Am J Manag Care"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2013-0374"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2014.001542"},{"key":"B28","first-page":"80","volume":"27","author":"Zafar SY","year":"2013","journal-title":"Oncology (Williston Park)"},{"key":"B29","first-page":"253","volume":"27","author":"Zafar SY","year":"2013","journal-title":"Oncology (Williston Park)"},{"key":"B32","first-page":"216","volume":"8","author":"Buffery D","year":"2015","journal-title":"Am Health Drug Benefits"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-014-0196-0"},{"key":"B34","doi-asserted-by":"crossref","first-page":"736","DOI":"10.18553\/jmcp.2006.12.9.736","volume":"12","author":"Stern D","year":"2006","journal-title":"J Manag Care Pharm"},{"key":"B35","unstructured":"Kantarjian H: The arrival of generic imatinib into the U.S. market: An educational event. http:\/\/www.ascopost.com\/issues\/may-25-2016\/the-arrival-of-generic-imatinib-into-the-us-market-an-educational-event\/"},{"key":"B36","unstructured":"Conti R: Why are cancer drugs commonly the target of schemes to extend patent exclusivity? http:\/\/healthaffairs.org\/blog\/2013\/12\/04\/why-are-cancer-drugs-commonly-the-target-of-schemes-to-extend-patent-exclusivity\/"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.11237"}],"container-title":["Journal of Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JOP.2016.014639","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T10:27:41Z","timestamp":1653820061000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JOP.2016.014639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["10.1200\/JOP.2016.014639"],"URL":"https:\/\/doi.org\/10.1200\/jop.2016.014639","relation":{},"ISSN":["1554-7477","1935-469X"],"issn-type":[{"value":"1554-7477","type":"print"},{"value":"1935-469X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"2017-01-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}